Related by context. All words. (Click for frequent words.) 70 cell lung cancer 70 Metastatic Colorectal Cancer 69 Renal Cell Carcinoma 69 Advanced Melanoma 69 Cutaneous T 68 Clinical Trial Results 67 Cell Lymphoma 67 Phase 2b Clinical Trial 67 Myelodysplastic Syndromes 67 Survival Benefit 67 Previously Treated 67 Metastatic Breast Cancer 66 Phase III Trial 66 Advanced Renal Cell 66 Phase III Clinical Trial 66 Newly Diagnosed 66 Metastatic 66 Antitumor Activity 65 Relapsed Refractory 65 Metastatic Melanoma 65 Carcinoma 65 Hepatocellular Carcinoma 65 Prolongs Survival 65 Randomized Phase II 65 Hormone Refractory Prostate Cancer 65 Improves Survival 65 Completes Enrollment 65 Patients Treated 65 Combination Therapy 64 Phase IIb Trial 64 Unresectable 64 Completes Patient Enrollment 64 Well Tolerated 64 Bladder Cancer 64 Improve Survival 64 Advanced Prostate Cancer 64 Chronic Myeloid Leukemia 64 Previously Untreated 64 Presents Preclinical Data 64 Chronic Hepatitis C 64 HDAC Inhibitor 64 Anti Tumor Activity 64 Newly Diagnosed Multiple Myeloma 64 Hsp# Inhibitor 64 Adjuvant Treatment 64 Meets Primary Endpoint 64 Chemotherapeutic Agents 64 Adjuvant Chemotherapy 64 Malignant Melanoma 63 Romidepsin 63 Metastatic Renal Cell Carcinoma 63 Pivotal Phase III 63 Myelofibrosis 63 ST Segment Elevation 63 Combination REOLYSIN R 63 Solid Tumors 63 Brentuximab Vedotin SGN 63 Metastatic Prostate Cancer 63 Irinotecan 63 Study Evaluating 63 HER2 Positive Breast Cancer 63 Improved Survival 63 Follicular Lymphoma 63 Metastases 63 Pooled Analysis 63 Soft Tissue Sarcoma 63 Placebo Controlled Trial 63 Chronic Lymphocytic Leukemia 63 Postmenopausal Women 63 Drug Candidate 63 Adjuvant Therapy 63 Demonstrates Potential 63 Pemetrexed 63 Phase IIb Clinical Trial 63 Investigational Drug 63 NSCLC 63 metastatic renal cell carcinoma 63 Palifosfamide 63 Squamous 63 Kinase Inhibitor 63 Epratuzumab 63 Complicated Skin 63 Pivotal Trial 63 Patients Treated With 63 Hormone Receptor Positive 62 Randomized Study 62 Oral Fingolimod 62 Initiates Phase II 62 Initiate Clinical Trial 62 Medullary Thyroid Cancer 62 CYT# potent vascular disrupting 62 Receives Orphan Drug Designation 62 Amrubicin 62 Present Preclinical Data 62 Anthracycline 62 Phase 2b Study 62 Presents Positive 62 Cancer Immunotherapy 62 metastatic colorectal 62 non squamous 62 Preclinical Data 62 Neoadjuvant 62 Erlotinib 62 Targeted Therapies 62 Cloretazine ® 62 Gastric Cancer 62 Pivotal Phase 62 Colorectal Cancer Patients 62 nab paclitaxel 62 Sapacitabine 62 Monotherapy 62 Immunotherapeutic 62 ZACTIMA 62 Mantle Cell Lymphoma 62 Combination Treatment 62 Tyrosine Kinase Inhibitor 62 refractory chronic lymphocytic 62 HGS ETR1 62 Cardiovascular Events 62 Castration Resistant Prostate Cancer 62 phase IIb trial 62 Successfully Completes Phase 62 gefitinib Iressa 62 Achieves Primary Endpoint 62 lung pancreatic 62 Lung Cancer Patients 62 FOLOTYN ® 62 Randomized Phase 62 Pivotal Clinical Trial 62 erlotinib Tarceva ® 62 Severe Sepsis 62 Diffuse Large B 62 Phase III Trials 62 Hepatocellular 62 IgG1 monoclonal antibody 62 MyVax R 62 Bevacizumab 62 Initiates Phase 62 Chronic Lymphocytic Leukemia CLL 61 Prospective Randomized 61 pan HDAC inhibitor 61 JAK Inhibitor 61 Proves Effective 61 Peginterferon 61 Demonstrates Significant 61 stage IIIB 61 ThermoDox R 61 Breast Cancer Patients 61 sunitinib Sutent 61 cutaneous T 61 recurrent metastatic ovarian cancer 61 Epidermal Growth Factor Receptor 61 Disease Progression 61 Advanced Pancreatic Cancer 61 Randomized Double Blind 61 Leukemias 61 Abiraterone Acetate 61 Overactive Bladder 61 MAGE A3 61 Sipuleucel T 61 IL# PE#QQR 61 stage IIIb IV 61 Seliciclib 61 Aflibercept 61 B Cell Lymphoma 61 Hepatocellular Carcinoma HCC 61 Novel Oral 61 Lupus Nephritis 61 Treatment Naive Patients 61 Multiple Myeloma 61 Rectal Cancer 61 hepatocellular cancer 61 cutaneous T cell 61 Subgroup Analysis 61 Preclinical Models 61 RNAi Therapeutic 61 Phase 2b Trial 61 Androgen Deprivation Therapy 61 interferon gamma 1b 61 Relapsed 61 cetuximab Erbitux 61 recurrent NSCLC 61 Initiates Enrollment 61 Elderly Patients 61 Benign Prostatic Hyperplasia 61 Bortezomib 61 Acute Ischemic Stroke 61 Patient Enrollment 61 IMA# 61 Investigational Compound 61 Combination Clinical Trial 61 Shows Promising 61 tumors GIST 61 Kinase Inhibitors 61 Breast Cancers 61 Initiates Clinical Trial 61 Pulmonary Arterial Hypertension 61 HER2 positive 61 cell carcinoma 61 Pivotal Study 61 Radiofrequency Ablation 61 II Clinical Trial 60 Pharmacokinetic Study 60 Alemtuzumab 60 Ulcerative Colitis 60 Pralatrexate 60 Statistically Significant 60 cell lymphoma CTCL 60 Idiopathic Pulmonary Fibrosis 60 Phase 2a Clinical Trial 60 Rheumatoid Arthritis Patients 60 Nymox NX 60 Refractory Hodgkin Lymphoma 60 Adenocarcinoma 60 Presents Preclinical 60 Clinical Outcome 60 Gemcitabine 60 Anti Tumor 60 Fluorouracil 60 Docetaxel 60 Hematological Malignancies 60 Apaziquone 60 advanced metastatic renal 60 Estrogen Receptor 60 Reports Preclinical Data 60 Node Positive 60 Novel Treatments 60 histone deacetylase HDAC inhibitor 60 Unfractionated Heparin 60 Improves Outcomes 60 Preclinical Study 60 castrate resistant prostate cancer 60 Safinamide 60 Advanced Colorectal Cancer 60 advanced hepatocellular carcinoma 60 LUX Lung 60 unresectable stage 60 squamous non 60 evaluating picoplatin 60 Relapsing Multiple Sclerosis 60 antibody MAb 60 Percutaneous Coronary Intervention 60 Breast Tumors 60 Diabetic Nephropathy 60 evaluating tivozanib 60 Cancer Therapies 60 unresectable Stage III 60 Breast Cancer Treatment 60 Hepatitis C Virus 60 alvespimycin 60 BRIM2 60 Initiates Clinical 60 Decitabine 60 dasatinib Sprycel 60 Phase #b/#a clinical 60 Myelodysplastic Syndrome MDS 60 phase IIb clinical 60 Gemzar ® 60 HER2 Positive 60 Liver Metastases 60 oral prodrug 60 FOLFOX6 60 unresectable locally advanced 60 Naive Patients 60 KRN# 60 Phase III Pivotal 60 Initiate Phase 60 recurrent glioblastoma multiforme 60 Nilotinib 60 lymphoid malignancies 60 Glufosfamide 60 Systemic Delivery 60 Diabetic Macular Edema 60 Infected Patients 60 Mouse Model 60 Gene Mutation 60 gastrointestinal stromal tumors GIST 60 Omacetaxine 60 Multicenter Randomized 60 ZOLINZA 60 Perifosine 60 myelofibrosis polycythemia vera 60 Drug Shows Promise 60 Prostate Cancer Patients 60 Relapsed Multiple Myeloma 60 Is Well Tolerated 60 RNAi Therapeutics 60 Doxil ® 60 Demonstrates Positive 59 Patients Receiving 59 Controlled Trial 59 SAR# [004] 59 neratinib 59 Interferon Beta 59 Orphan Diseases 59 Ovarian Cancer Patients 59 metastatic hormone refractory 59 non squamous NSCLC 59 platinum refractory 59 AEG# 59 Randomized Double blind 59 Gastrointestinal Stromal Tumors 59 Antiangiogenic 59 sorafenib tablets 59 MGd 59 Lung Cancer Trial 59 Tolerability 59 HCV Protease Inhibitor 59 Cancer Incidence Mortality 59 BRIM3 59 Localized Prostate Cancer 59 PANVAC VF 59 Emerging Therapies 59 Carotid Stenting 59 ongoing Phase 1b 59 EGFR TKI 59 Initiates Phase III 59 Heart Failure Patients 59 Factor Receptor 59 Capecitabine 59 Demonstrates Potent 59 Mayo Clinic Study Finds 59 Pazopanib 59 Dose Escalation 59 carcinoid tumors 59 Hedgehog Pathway Inhibitor 59 Treating Chronic 59 Anticancer Compound 59 Stereotactic Body Radiation Therapy 59 Recombinant Human 59 trastuzumab DM1 T DM1 59 5 fluorouracil leucovorin 59 resistant hormone refractory 59 Begins Dosing 59 Protease Inhibitor 59 L BLP# 59 lung cancers 59 Taxane 59 Diabetic Neuropathy 59 ovarian esophageal 59 Chronic Heart Failure 59 Carfilzomib 59 Dupuytren Contracture 59 Investigational Agent 59 Renal Cancer 59 Pertuzumab 59 Metastatic Pancreatic Cancer 59 Neoadjuvant Chemotherapy 59 bladder cancers 59 Spectrum Pharmaceuticals Announces 59 Enzastaurin 59 Liver Cancer 59 Quinamed 59 Peginterferon alfa 2b 59 Myelodysplastic Syndrome 59 Tesetaxel 59 lymphoma CTCL 59 seminoma 59 MAGE A3 ASCI 59 PDX pralatrexate 59 Autoimmune Disease 59 Shows Efficacy 59 Sorafenib 59 Treatment Naïve 59 Long Term Efficacy 59 Meta Analysis 59 Glioblastoma Multiforme 59 Granted Orphan Drug 59 Oral Formulation 59 Completes Dosing 59 Newly Diagnosed Patients 59 Pancreatic Adenocarcinoma 59 Tumor Response 59 Study Showed 59 Plus Ribavirin 59 Patients Undergoing 59 Trastuzumab DM1 59 receptor tyrosine kinase inhibitor 59 nonsmall cell lung cancer 59 Tezampanel 59 KRAS mutation 59 metastatic renal cell 59 Files IND 59 Voreloxin 59 Carboplatin 59 autologous cellular immunotherapy 59 Vaccine Adjuvant 59 medically inoperable 59 Brain Metastases 59 Aliskiren 59 Lymphomas 59 Phase #/#a trial 59 Metastatic Disease 59 Esophageal Cancer 59 targeting CD# 59 Complete Remission 59 Folfox 59 Advanced Solid Tumors 59 Phase Ib II 59 Intracranial Aneurysms 59 Lung Cancers 59 Receives Positive Opinion 59 Low Dose 59 huC# DM4 59 Clostridium difficile Infection 59 Investigational Treatment 59 metastatic castrate resistant 59 ASCO GI 59 NDA Submission 59 Therapeutic Potential 59 Enzyme Replacement Therapy 59 Psoriasis Patients 59 vinca alkaloid 59 Chemoradiation 59 Randomized Controlled Trials 59 PXD# 59 Elagolix 59 mapatumumab 59 Slow Progression 59 Dose Escalation Study 59 enzastaurin 59 Cloretazine 59 Ranolazine 59 sunitinib malate 59 Carcinomas 59 metastatic breast 59 Treatment Resistant 59 Malignancies 58 Paclitaxel Carboplatin 58 HRPC 58 Efficacious 58 panitumumab Vectibix 58 Treatment Experienced 58 HER2 positive metastatic breast 58 Lenalidomide 58 Thyroid Cancer 58 OncoVEX GM CSF 58 Multiple Myeloma Patients 58 Carboplatin Paclitaxel 58 Initiate Phase III 58 Chronic Myelogenous Leukemia 58 MEK Inhibitor 58 Chronic Hepatitis B 58 Therapy Evaluation 58 JAK2 Inhibitor 58 axitinib 58 Glioma 58 medullary thyroid cancer 58 essential thrombocythemia ET 58 AVOREN 58 TNF Blockers 58 unresectable 58 Plaque Psoriasis 58 PNP inhibitor 58 Announces Poster Presentations 58 depsipeptide 58 Predict Response 58 Gefitinib 58 Diabetic Patients 58 fallopian tube cancers 58 Anticancer Drugs 58 prostate cancer CRPC 58 MKC# MKC# PP 58 hepatocellular carcinoma HCC 58 PSMA ADC 58 Hematological Cancers 58 Adjuvant 58 Acute Coronary Syndromes 58 investigational humanized monoclonal antibody 58 Randomized Controlled 58 bevacizumab Avastin 58 Drug Resistant 58 Relapsed Refractory Multiple Myeloma 58 Pegylated Interferon 58 IMC A# 58 investigational oral inhibitor 58 Phase IIa Clinical Trial 58 Novel Antibiotic 58 Adenoma 58 Hypercholesterolemia 58 Phase 1b Clinical Trial 58 SCCHN 58 Platelet Inhibition 58 Kit CD# positive 58 metastatic neuroendocrine tumors 58 Initiates Phase 2b 58 Uterine Fibroid Embolization 58 ARRY # 58 Targeted Therapy 58 Lung Cancer Drug 58 Insulin Resistance 58 invasive bladder 58 PEGylated interferon beta 1a 58 DIRECT Trial 58 Pafuramidine 58 Hemodialysis Patients 58 basal cell carcinoma BCC 58 dasatinib Sprycel ® 58 Randomized Double Blind Placebo 58 Antiviral Activity 58 Acute Myocardial Infarction 58 Bavituximab 58 Randomized Controlled Trial 58 Telaprevir VX 58 Vidaza azacitidine 58 Trastuzumab 58 Increased Risk 58 Advaxis Phase 58 INSPIRE Trial Phase III 58 lintuzumab 58 Personalized Immunotherapy 58 Randomized Phase III 58 olaparib 58 Randomized Trials 58 biliary tract cancer 58 gastrointestinal stromal tumors 58 Cethromycin 58 HNSCC 58 Phase 2a Trial 58 Renal Tumors 58 hormone deprivation 58 Elotuzumab 58 Drug Eluting 58 Oral Mucositis 58 Vaccine Protects Against 58 Trial Evaluating 58 Vidaza ® 58 FDA Okays 58 lung carcinomas 58 Novel Mechanism 58 Universal Flu Vaccine 58 epithelial tumors 58 standard chemotherapy regimen 58 Small Molecule 58 Paraplatin ® 58 metastatic RCC 58 AA Amyloidosis 58 Dose Ranging Study 58 Taxotere ® 58 Submits NDA 58 Severe Asthma 58 See CLINICAL PHARMACOLOGY 58 Shows Promise Against 58 Stomach Cancer 58 non resectable 58 Acute Myeloid Leukemia 58 Solazed TM 58 Hepatitis C Virus HCV 58 anti EGFR antibody 58 BR.# 58 Prognostic Significance 58 Breast Cancer Recurrence 58 SPRYCEL ® 58 Ozarelix 58 monoclonal antibody conjugated 58 HuMax EGFr 58 Cloretazine R 58 ixabepilone 58 sorafenib Nexavar 58 metastatic malignant 58 Adjunctive Therapy 58 familial amyloidotic polyneuropathy FAP 58 Phase 2a Study 58 Prospective Multicenter 58 Chronic lymphocytic leukemia 58 Bronchiectasis 58 Chemotherapy Regimen 58 Metabolic Efficiency 58 Panzem R NCD 58 malignant pleural mesothelioma 58 Phase III Clinical Trials 58 TTF Therapy 58 ALCL 58 bevacizumab Avastin ® 58 FDA Accepts 58 Anti TNF 58 sarcoma melanoma 58 Monoclonal Antibodies 58 Clinical Efficacy 58 Hyperlipidemia 58 adalimumab Humira 58 Hedgehog Pathway 58 Aplidin R 58 SABCS 58 Chronic Sinusitis 58 imatinib Gleevec ® 58 Golimumab 58 Enlarged Prostate 58 Inhaled Liposomal Ciprofloxacin 58 investigational immunotherapy 58 ALN TTR 58 Zolinza 58 PEGylated Fab fragment 58 Commences Phase 58 #I TM# 58 Exherin TM 58 apoptosis inducer 58 Mitoxantrone 58 Anti CD# Antibody 58 metastatic colorectal cancer 58 Autoimmune Diseases 58 ritonavir boosted 58 Anticancer Drug 57 renal cell carcinoma 57 YONDELIS 57 Vaccine Candidate 57 5 FU leucovorin 57 heavily pretreated 57 FOLFIRI 57 stage IIIB IV 57 including eniluracil ADH 57 Therapeutic Vaccine 57 Therapeutic Efficacy 57 Natalizumab 57 Venous Thromboembolism 57 forodesine 57 Antigen Specific 57 Allergic Rhinitis 57 angiogenesis inhibitor 57 Atypical Hemolytic Uremic Syndrome 57 Renal Cell Carcinoma RCC 57 Topline Results 57 Stage IIB 57 Bosentan 57 Multicenter Phase 57 Acute Myeloid Leukemia AML 57 Synta Announces 57 Analytical Tool 57 Pharmacokinetics PK 57 SUTENT ® 57 dependent kinase inhibitor 57 Disease Modifying 57 YONDELIS R 57 ganetespib 57 Pegylated 57 Receives Orphan Drug 57 CR# vcMMAE 57 Degarelix 57 Progressive Multifocal Leukoencephalopathy 57 trabectedin 57 fosbretabulin 57 recurrent ovarian cancer 57 oral nucleoside analogue 57 Chemotherapy Induced Anemia 57 Cerebril TM 57 docetaxel Taxotere ® 57 metastatic pancreatic 57 MKC# MT 57 Gleevec resistant 57 SCH # 57 Clofarabine 57 Stage IIIb 57 Ambrisentan 57 ORENCIA ® 57 Ischemic 57 R roscovitine 57 AVASTIN 57 Viral Suppression 57 Humanized Anti 57 Treatment Regimen 57 Phase Ib clinical trials 57 Anticoagulants 57 Prostate Cancers 57 Bosutinib 57 PROSTASCINT R 57 Skin Cancers 57 EGFr 57 Vandetanib 57 Lupus Drug 57 Completes Patient Enrolment 57 metastatic castration resistant 57 Improve Outcomes 57 Tamibarotene 57 Treatment Naive 57 Systematic Review 57 Temsirolimus 57 colorectal liver metastases 57 Secondary Hyperparathyroidism 57 Vitro Activity 57 Pancreatic Cancer 57 Cardiotoxicity 57 Pirfenidone 57 Breast Density 57 Serious Infections 57 Sangamo BioSciences Announces 57 novel emulsion formulation 57 completely resected 57 taxane therapy 57 Antiviral Therapy 57 cancer mCRC 57 Aurora Kinase 57 Squamous Cell Carcinoma 57 relapsed multiple myeloma 57 Xcytrin R 57 Kamada AAT 57 thalidomide Thalomid 57 Midsized Businesses 57 Myocardial Ischemia 57 Unstable Angina 57 Radioimmunotherapy 57 Civacir 57 tubulin inhibitor 57 metastatic gastric 57 targeted radiotherapeutic 57 Fludara ® 57 Diabetic Foot Ulcer 57 Increased Mortality 57 Motesanib 57 ISTODAX ® 57 ENDEAVOR IV 57 PROVENGE ® 57 Dapagliflozin 57 Potent Anti 57 Bivalirudin 57 Aggressive Prostate Cancer 57 intravesical infusion therapy 57 commonly mutated genes 57 velafermin 57 Bezielle 57 Cardiovascular Outcomes 57 Endometrial Cancer 57 Philadelphia Chromosome Positive 57 Rheumatoid Arthritis Drug 57 bladder ovarian 57 Denufosol 57 Friedreich Ataxia FRDA 57 NSCLC tumors 57 TORISEL 57 Single Dose 57 Newly Diagnosed Breast Cancer 57 Evoltra ® 57 Myeloma Patients 57 Resistant Hypertension 57 Xelox 57 metastatic GIST 57 pancreatic NET 57 Pegylated Liposomal Doxorubicin 57 squamous 57 Overactive Bladder OAB 57 Annamycin 57 Dasatinib 57 neuroendocrine cancers 57 Knee Osteoarthritis 57 Autologous Stem Cell Transplantation 57 papillary renal cell carcinoma 57 xenograft models 57 Ofatumumab 57 Anticancer Activity 57 Albuferon TM 57 Monoclonal Antibody 57 resistant ovarian cancer 57 Panzem NCD 57 Atopic Dermatitis 57 Stem Cell Transplants 57 erythematosus 57 Bone Metastases 57 Radical Prostatectomy 57 Orally Active 57 Nexavar sorafenib 57 refractory multiple myeloma 57 brand ciclesonide HFA 57 Velcade bortezomib 57 Prostate Cancer Treatment 57 Thromboembolism 57 Cancer Vaccines 57 multicenter Phase II 57 NICE Recommends 57 Malignant Glioma 57 temsirolimus 57 Therapeutic Competitors Companies 57 severe oral mucositis 57 Postmenopausal Osteoporosis 57 FOLFOX6 chemotherapy regimen 57 amrubicin 57 panobinostat 57 Treated Patients 57 LHRH receptor positive 57 Advanced Ovarian Cancer 57 Sirolimus Eluting Stent 57 Nexavar ® 57 CA4P 57 Cholangiocarcinoma 57 Test Detects 57 recurrent GBM 57 severe hypersensitivity reactions 57 Embolization 57 5 Fluorouracil 57 PRN FDA Approves 57 Tumor Growth 57 Statin Therapy 57 Cancer Patients Treated 57 Receives Fast Track 57 Papillary 57 pancreatic adenocarcinoma 57 Vitaxin 57 Drug Fails 57 eosinophilic asthma 57 paclitaxel Taxol R 57 novel VDA molecule 57 Allovectin 7 R 57 cediranib 57 leukemia AML 57 Chronic Myelogenous Leukemia CML 57 leukemia CLL 57 R roscovitine CDK cyclin 57 Camptosar ® 57 Renal Cell Cancer 57 Controlled Study 57 Line Metastatic Colorectal 57 Progenitor Cells 57 Observational Study 57 estramustine 57 Tanespimycin 57 Picoplatin Efficacy After 57 Invasive Breast Cancer 57 Entereg R 56 multi kinase inhibitor 56 IV melanoma 56 Pegasys ® 56 registrational trial 56 IMC #B 56 Antifungals 56 vandetanib 56 Demonstrates Sustained 56 hypereosinophilic syndrome 56 AP# [003] 56 ASA# 56 Interferon Alfa 56 Endothelial Cells 56 Files Investigational 56 AAG geldanamycin analog 56 gemcitabine Gemzar 56 invasive candidiasis 56 systemic anaplastic large 56 metastatic colorectal carcinoma 56 Imatinib 56 Tumor Targeting 56 cisplatin chemotherapy 56 neuroendocrine tumors 56 ST Elevation Myocardial 56 mertansine 56 TO AVOID PREGNANCY WHILE 56 Novel Small Molecule 56 paclitaxel Taxol 56 corticotropin injection 56 recurrent glioma 56 KRAS wild 56 Skin Structure Infections ABSSSI 56 Clinical Trial Evaluating 56 Adenomas 56 Permanent Prostate Brachytherapy 56 Prednisone Against Refractory 56 registrational Phase 56 Dacogen injection 56 neoadjuvant therapy 56 Tumor Necrosis Factor 56 oral proteasome inhibitor 56 Meet Primary Endpoint 56 Study Demonstrates 56 Diabetic Neuropathic Pain 56 liposomal amphotericin B 56 Demonstrated Significant 56 predictive biomarkers 56 metastatic liver 56 recurrent metastatic 56 Blood Pressure Lowering 56 Relapsing Remitting Multiple Sclerosis 56 pertuzumab 56 vascular disrupting agent 56 trastuzumab Herceptin ® 56 candidates Azedra TM 56 Genes Predict 56 HoFH 56 cell lymphoma ALCL 56 Lacosamide 56 Gets FDA Clearance 56 Vorinostat 56 advanced NSCLC 56 neoadjuvant 56 Disease Modification 56 pralatrexate injection folate analogue 56 Romiplostim 56 ErbB2 positive 56 refractory cutaneous T 56 Fixed Dose 56 HCV SPRINT 56 oncolytic virus therapies 56 Therapeutic Targets 56 lung ovarian 56 CYC# 56 PKC# 56 B Cell Malignancies 56 Erectile Dysfunction Drug 56 RGB # 56 PRT# 56 Relapsed Refractory Aggressive 56 squamous cell lung cancer 56 Copegus R 56 Subtypes 56 Daclizumab 56 relapsed ovarian cancer 56 Cetuximab Erbitux 56 Neuroendocrine Tumors 56 Adalimumab 56 breast pancreatic 56 Treatment Reduces 56 TTR amyloidosis 56 STRIDE PD 56 Phase III Pivotal Trial 56 Deforolimus 56 Hodgkin lymphoma HL 56 Myocardial Infarction Study 56 ALN HPN 56 sunitinib Sutent ® 56 CTAP# Capsules 56 GISTs 56 Nitazoxanide 56 follicular non 56 bone metastasis 56 Autoimmune Disorders 56 Peginterferon Alfa 2b 56 Molecular Diagnostic Test 56 Acute Exacerbations 56 Inflammatory Diseases 56 Fabry Disease 56 B CLL 56 antibody MT# 56 Crohn disease CD 56 randomized Phase III 56 Gene Linked 56 advanced unresectable 56 Zybrestat 56 Clinical Trial Data 56 prostate cancer mCRPC 56 Double Blind Placebo 56 Maribavir 56 Predict Risk 56 Randomized Clinical Trial 56 Liver Tumors 56 agonistic human 56 Inflammatory Disease 56 MCSP respectively 56 Outpatient Setting 56 Clinical Trials Review 56 Dendritic Cells 56 metastatic ocular 56 Therapeutic Antibodies 56 trastuzumab Herceptin R 56 CIMZIA ™ 56 OPAXIO 56 topoisomerase II inhibitor 56 Azacitidine 56 neoadjuvant treatment 56 Dose Ranging 56 Inhibits 56 phase IIb study 56 keloid scarring 56 Gastrointestinal Disorders 56 HGS ETR1 mapatumumab 56 Genasense ® 56 Xeloda capecitabine 56 Tumor Cell 56 Tarceva erlotinib 56 metastatic renal 56 PROVENGE sipuleucel T 56 PD LID 56 Oncolytic Reovirus 56 invasive lobular carcinoma 56 ZACTIMA TM ZD# 56 Genes Identified 56 Breast Cancer Cells 56 Neuvenge 56 VEGFR2 inhibitor 56 Rheumatoid Arthritis 56 mGluR5 negative 56 nonmetastatic 56 androgen independent 56 Virus Infection 56 assessing T DM1 56 Tyrosine Kinase Inhibitors 56 Patient Outcomes 56 Trofex 56 Cypher Sirolimus 56 Cell Non Hodgkin 56 Teva Provides Update 56 Allogeneic 56 relapsed refractory multiple myeloma 56 liposomal doxorubicin 56 Herceptin trastuzumab 56 LENALIDOMIDE 56 BRAF inhibitor 56 atypical Hemolytic Uremic Syndrome 56 Contrast Agents 56 Prostate Biopsy 56 InNexus Biotechnology Announces 56 fallopian tube carcinoma 56 Regimens 56 prostate cancer HRPC 56 aflibercept